Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;10(3):260-267.
doi: 10.14740/jocmr3325w. Epub 2018 Jan 26.

The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study

Sebastiao Freitas de Medeiros  1   2 , Laura Camila Antunes Angelo  1 , Matheus Antonio Souto de Medeiros  2 , Camila Regis Banhara  2 , Bruna Barcelo Barbosa  2 , Marcia Marly Winck Yamamoto  2
Affiliations

The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study

Sebastiao Freitas de Medeiros et al. J Clin Med Res. 2018 Mar.

Abstract

Background: The aim of this study was to examine the role of C-peptide as a biological marker of cardiometabolic risk in polycystic ovary syndrome (PCOS).

Methods: This case-control study enrolled 385 PCOS patients and 240 normal cycling women. Anthropometric and clinical variables were taken at first visit. Fasting C-peptide, glucose, lipids, and hormone measurements were performed. Simple and multiple correlations between C-peptide and other variables associated with dysmetabolism and cardiovascular disease were examined.

Results: C-peptide was well correlated with several anthropometric, metabolic, and endocrine parameters. In PCOS patients, stepwise multiple regression including C-peptide as the criterion variable and other predictors of cardiovascular disease risk provided a significant model in which the fasting C-peptide/glucose ratio, glucose, body weight, and free estrogen index (FEI) were retained (adjusted R2 = 0.988, F = 7.161, P = 0.008).

Conclusion: C-peptide levels alone or combined with C-peptide/glucose ratio, glucose, body weight, and FEI provided a significant model to identify PCOS patients with higher risk of future cardiometabolic diseases.

Keywords: C-peptide; Cardiovascular disease; Dysglycemia; Dyslipidemia; Polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors fully declare there is no financial or other conflict of interest.

References

    1. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520. doi: 10.1210/er.2015-1104. - DOI - PMC - PubMed
    1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800. doi: 10.1210/er.18.6.774. - DOI - PubMed
    1. Steiner DF. The proinsulin C-peptide—a multirole model. Exp Diabesity Res. 2004;5(1):7–14. doi: 10.1080/15438600490424389. - DOI - PMC - PubMed
    1. Saisho Y. Postprandial C-Peptide to Glucose Ratio as a Marker of beta Cell Function: Implication for the Management of Type 2 Diabetes. Int J Mol Sci. 2016;17(5):744. doi: 10.3390/ijms17050744. - DOI - PMC - PubMed
    1. Wahren J, Shafqat J, Johansson J, Chibalin A, Ekberg K, Jornvall H. Molecular and cellular effects of C-peptide—new perspectives on an old peptide. Exp Diabesity Res. 2004;5(1):15–23. doi: 10.1080/15438600490424479. - DOI - PMC - PubMed

LinkOut - more resources